• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名患有哮喘-慢性阻塞性肺疾病重叠综合征的患者因β2激动剂引发严重震颤。

A severe tremor caused by a beta2 agonist in a patient with asthma-chronic obstructive pulmonary disease overlap.

作者信息

Nakajima Kota, Momo Kenji

机构信息

Department of Pharmacy Izumi Memorial Hospital Tokyo Japan.

Department of Hospital Pharmaceutics School of Pharmacy, Showa University Tokyo Japan.

出版信息

Clin Case Rep. 2024 Jul 31;12(8):e9137. doi: 10.1002/ccr3.9137. eCollection 2024 Aug.

DOI:10.1002/ccr3.9137
PMID:39091622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11291297/
Abstract

A 46-year-old male developed respiratory distress due to asthma-chronic obstructive pulmonary disease overlap and experienced severe tremor caused by beta2 agonist inhalant. We present our successful experience with tizanidine administration.

摘要

一名46岁男性因哮喘-慢性阻塞性肺疾病重叠综合征出现呼吸窘迫，并因吸入β2激动剂而出现严重震颤。我们介绍了使用替扎尼定治疗成功的经验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92df/11291297/6c7eff8fc595/CCR3-12-e9137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92df/11291297/b304bfa94694/CCR3-12-e9137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92df/11291297/6c7eff8fc595/CCR3-12-e9137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92df/11291297/b304bfa94694/CCR3-12-e9137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92df/11291297/6c7eff8fc595/CCR3-12-e9137-g002.jpg

相似文献

1
A severe tremor caused by a beta2 agonist in a patient with asthma-chronic obstructive pulmonary disease overlap.一名患有哮喘-慢性阻塞性肺疾病重叠综合征的患者因β2激动剂引发严重震颤。
Clin Case Rep. 2024 Jul 31;12(8):e9137. doi: 10.1002/ccr3.9137. eCollection 2024 Aug.
2
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）的药理学管理。
Expert Opin Pharmacother. 2020 Feb;21(2):213-231. doi: 10.1080/14656566.2019.1701656.
3
Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study.台湾哮喘和 COPD 重叠（ACO）的负担：一项基于全国人口的研究。
BMC Pulm Med. 2018 Jan 25;18(1):16. doi: 10.1186/s12890-017-0571-7.
4
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.稳定期慢性阻塞性肺疾病的诊断与药物治疗：芬兰指南
Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):291-307. doi: 10.1111/bcpt.12366. Epub 2015 Jan 22.
5
Disease Burden of Patients with Asthma/COPD Overlap in a US Claims Database: Impact of ICD-9 Coding-based Definitions.美国索赔数据库中哮喘/慢性阻塞性肺疾病重叠患者的疾病负担：基于国际疾病分类第九版（ICD-9）编码定义的影响。
COPD. 2017 Apr;14(2):200-209. doi: 10.1080/15412555.2016.1257598. Epub 2017 Jan 19.
6
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.吸入长效β2受体激动剂治疗阻塞性肺疾病的获益-风险评估
Drug Saf. 2004;27(10):689-715. doi: 10.2165/00002018-200427100-00001.
7
Cardioselective beta-blockers for reversible airway disease.用于可逆性气道疾病的心脏选择性β受体阻滞剂。
Cochrane Database Syst Rev. 2002(1):CD002992. doi: 10.1002/14651858.CD002992.
8
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.慢性阻塞性肺疾病（COPD）队列中哮喘-COPD重叠综合征患者的治疗趋势：一项真实世界调查的结果
Int J Chron Obstruct Pulmon Dis. 2017 Jun 15;12:1753-1763. doi: 10.2147/COPD.S136314. eCollection 2017.
9
Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.吸入性糖皮质激素与长效β2受体激动剂联合治疗哮喘-慢性阻塞性肺疾病重叠综合征。
Int J Chron Obstruct Pulmon Dis. 2016 Nov 8;11:2797-2803. doi: 10.2147/COPD.S114964. eCollection 2016.
10
Phenotypes of Asthma-Chronic Obstructive Pulmonary Disease Overlap.哮喘-慢性阻塞性肺疾病重叠的表型。
Immunol Allergy Clin North Am. 2022 Aug;42(3):645-655. doi: 10.1016/j.iac.2022.04.009. Epub 2022 Jun 30.

本文引用的文献

1
Parkinson's Disease and Parkinsonism.帕金森病和帕金森综合征。
Am J Med. 2019 Jul;132(7):802-807. doi: 10.1016/j.amjmed.2019.03.001. Epub 2019 Mar 16.
2
Lower metabolic clearance of tizanidine in Japanese subjects.替扎尼定在日本受试者中的代谢清除率较低。
Int J Clin Pharmacol Ther. 2013 Dec;51(12):986-8. doi: 10.5414/CP201964.
3
[Clinical survey of tizanidine-induced adverse effects--impact of concomitant drugs providing cytochrome P450 1A2 modification--].替扎尼定所致不良反应的临床调查——细胞色素P450 1A2修饰的伴随用药的影响——
Yakugaku Zasshi. 2013;133(2):275-81. doi: 10.1248/yakushi.12-00222.
4
Tremor and β(2)-adrenergic agents: is it a real clinical problem?震颤与β（2）-肾上腺素能制剂：这是一个真正的临床问题吗？
Pulm Pharmacol Ther. 2012 Feb;25(1):4-10. doi: 10.1016/j.pupt.2011.12.004. Epub 2011 Dec 24.
5
Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.CYP1A2 抑制剂美西律对替扎尼定药代动力学和药效学的影响。
J Clin Pharmacol. 2010 Mar;50(3):331-7. doi: 10.1177/0091270009341961. Epub 2009 Sep 29.
6
Tizanidine-induced hypotension in patients with liver cirrhosis.肝硬化患者中替扎尼定诱发的低血压
Eur J Clin Pharmacol. 2008 Jun;64(6):647-8. doi: 10.1007/s00228-008-0469-7.
7
Drug interaction of tizanidine and ciprofloxacin: case report.替扎尼定与环丙沙星的药物相互作用：病例报告
Clin Pharmacol Ther. 2006 Dec;80(6):717-9. doi: 10.1016/j.clpt.2006.08.017.
8
Practice parameter: therapies for essential tremor [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数：特发性震颤的治疗方法[已退休]：美国神经病学学会质量标准小组委员会报告
Neurology. 2005 Jun 28;64(12):2008-20. doi: 10.1212/01.WNL.0000163769.28552.CD. Epub 2005 Jun 22.
9
Drug interaction of tizanidine and fluvoxamine.替扎尼定与氟伏沙明的药物相互作用。
Clin Pharmacol Ther. 2004 Nov;76(5):509-10. doi: 10.1016/j.clpt.2004.08.003.
10
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.替扎尼定在体外主要由细胞色素P450 1A2代谢。
Br J Clin Pharmacol. 2004 Mar;57(3):349-53. doi: 10.1046/j.1365-2125.2003.02028.x.